Cardiovascular Disease and NASH

Crossmark: check for updates

Authors

  • Erika Rabelo Forte de Siqueira Department of Gastroenterology, University of Pernambuco School of Medicine, Pernam- buco, Brazil; Liver Institute of Pernambuco, Pernambuco, Brazil
  • Leila Maria Moreira Beltrao Pereira Department of Gastroenterology, University of Pernambuco School of Medicine, Pernam- buco, Brazil; Liver Institute of Pernambuco, Pernambuco, Brazil
  • Arun Jayant Sanyal Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Vir- ginia Commonwealth University School of Medicine, Richmond, VA, USA

DOI:

https://doi.org/10.17140/lroj-1-107

Keywords:

NAFLD: Non-alcoholic fatty liver disease, CVD: Cardiovascular disease, MetS: Metabolic Syndrome, AF: Atrial Fibrillation, CAC: Coronary Artery Calcium, CT: Computed Tomography, FFAs: Free Fatty Acids, NASH: Non alcoholic steatohepatitis, LDL-C: Low-density Lipoprotein-Cholesterol, HMGCR: HMG CoA Reductase, VLDL: Very-low-density lipoprotein, CAD: Coronary Artery Disease

Abstract

Non-alcoholic fatty liver disease (NAFLD) and Non-alcoholic steatohepatitis (NASH) are associated with cardiovascular events and Metabolic Syndrome (MetS). NAFLD is considered to be a hepatic manifestation of MetS and has become an important public health issue because of its high prevalence. It is currently being considered an independent Cardiovascular disease (CVD) risk factor. In this clinical review, we will briefly review the mechanisms linking NAFLD to the complement system, endothelial dysfunction and the atherosclerosis.

References

Masuoka HC, Chalasani N. Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann N Y Acad Sci. 2013; 1281: 106-122. doi: 10.1111/nyas.12016

Wree A, Broderick L, Canbay A, et al. From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol. 2013; 10: 627-636. doi: 10.1038/ nrgastro.2013.149

Williams CD, Stengel J, Asike MI, et al. Prevalence of non-alcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011; 140: 124-131. doi: 10.1053/j.gastro.2010.09.038

Wong VW, Wong GL, Choi PC, et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut. 2010; 59: 969-974. doi: 10.1136/ gut.2009.205088

Dunn W, Xu R, Wingard DL, et al. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based co-hort study. Am J Gastroenterol. 2008; 103: 2263-2271. doi: 10.1111/j.1572-0241.2008.02034.x

Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol. 2008; 49: 608-612. doi: 10.1016/j.jhep.2008.06.018

Kuang-Chun Hu, Horng-Yuan Wang, Sung-Chen Liu, et al. Nonalcoholic fatty liver disease: updates in noninvasive diag-nosis and correlation with cardiovascular disease. World J Gas-troenterol. 2014; 20(24): 7718-7729. doi: 10.3748/wjg.v20. i24.7718

Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013; 10: 330-344. doi: 10.1038/nrgas-tro.2013.41

Oni ET, Agatston AS, Blaha MJ, et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Athero-sclerosis. 2013; 230: 258-267. doi: 10.1016/j.atherosclero-sis.2013.07.052

Targher G, Mantovani A, Pichiri I, et al. Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes. Clin Sci (Lond). 2013; 125(6): 301-309. doi: 10.1042/CS20130036

Targher G, Valbusa F, Bonapace S, et al. Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. PLoS One. 2013; 8: 57183. doi: 10.1371/journal.pone.0057183

Abdulla J, Asferg C, Kofoed KF. Prognostic value of absence or presence of coronary artery disease determined by 64-slice computed tomography coronary angiography a systematic re-view and meta-analysis. Int J Cardiovasc Imaging. 2011; 27: 413-420. doi: 10.1007/s10554-010-9652-x

Stepanova M, Younossi ZM. Independent association be-tween nonalcoholic fatty liver disease and cardiovascular dis-ease in the US population. Clin Gastroenterol Hepatol. 2012; 10: 646-650. doi: 10.1016/j.cgh.2011.12.039

Arslan U, Türkoğlu S, Balcioğlu S, et al. Association be-tween nonalcoholic fatty liver disease and coronary artery dis-ease. Coron Artery Dis. 2007; 18(6): 433-436.

Schwimmer JB, Pardee PE, Lavine JE, et al. Cardiovascular risk factors and the metabolic syndrome in pediatric nonalco-holic fatty liver disease. Circulation. 2008; 118(3): 277-283. doi: 10.1161/CIRCULATIONAHA.107.739920

Hamaguchi M, Kojima T, Takeda N, et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol. 2007; 13: 1579-1584. doi: 10.3748/wjg. v13.i10.1579

Wong VW, Wong GL, Yip GW, et al. Coronary artery dis-ease and cardiovascular outcomes in patients with nonalcoholic fatty liver disease. Gut. 2011; 60: 1721-1727. doi: 10.1136/ gut.2011.242016

Hertle E, Stehouwer CDA, van Greevenbroek MMJ. The complement system in human cardiometabolic disease. Mo-lecular Immunology. 2014; 61: 135-148. doi: 10.1016/j.mo-limm.2014.06.031

Bellentani S, Scaglioni F, Marino M, et al. Epidemiology of non-alcoholic fatty liver disease. Dig Dis. 2010; 28: 155-161. doi: 10.1159/000282080

Speidl WS, Kastl SP, Huber K, et al. Complement in athero-sclerosis: friend or foe? J Thromb Haemost. 2011; 9: 428-440. doi: 10.1111/j.1538-7836.2010.04172.x

Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2011; 363(14): 1341-1350. doi: 10.1056/NEJMra0912063

Sinner MF, Wang N, Fox CS, et al. Relation of circulating liver transaminase concentrations to risk of new-onset atrial fi-brillation. Am J Cardiol. 2013; 111: 219-224. doi: 10.1016/j.am-jcard.2012.09.021

Stefano Ballestri, Amedeo Lonardo, Stefano Bonapace, et al. Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J Gastro-enterol. 2014; 20(7): 1724. doi: 10.3748/wjg.v20.i7.1724

Blake GJ, Otvos JD, Rifai N, et al. Low-density lipopro-tein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascu-lar disease in women. Circulation. 2002; 106: 1930-1937. doi: 10.1161/01.CIR.0000033222.75187.B9

Cromwell WC, Otvos JD. Low-density lipoprotein particle number and risk for cardiovascular disease. Curr Atheroscler Rep. 2004; 6: 381-387.

Toledo FGS, Sniderman AD, Kelley DE. Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipid-emia in type 2 diabetes. Diabetes Care. 2006; 29: 1845-1850. doi: 10.2337/dc06-0455

Rashid S, Watanabe T, Sakaue T, et al. Mechanisms of HDL-lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin Biochem. 2003; 36: 421-429. doi: 10.1016/S0009-9120(03)00078-X

Sookoian S, Gianotti TF, Rosselli MS, et al. Liver transcrip-tional profile of atherosclerosis- related genes in human nonal-coholic fatty liver disease. Atherosclerosis. 2011; 218(2): 378- 385. doi: 10.1016/j.atherosclerosis.2011.05.014

Hae-Ki Min, Ashwani Kapoor, Michael Fuchs, et al. In-creased hepatic synthesis and dysregulation of cholesterol me-tabolism is associated with the severity of nonalcoholic fatty liv-er disease. Cell Metabolism. 2012; 15: 665-674. doi: 10.1016/j. cmet.2012.04.004

Horton JD, Shimomura I, Brown MS, Hammer RE, Gold-stein JL, Shimano H. Activation of cholesterol synthesis in pref-erence to fatty acid synthesis in liver and adipose tissue of trans-genic mice overproducing sterol regulatory element-binding protein-2. J Clin Invest. 1998; 101: 2331-2339. doi: 10.1172/ JCI2961

Siddiqui MS, Fuchs M, Idowu M, et al. The histologic sever-ity and progressionto cirrhosis impacts atherogenic lipoprotein profile in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014.

Downloads

Published

2015-07-29

How to Cite

Erika Rabelo Forte de Siqueira, Leila Maria Moreira Beltrao Pereira, & Arun Jayant Sanyal. (2015). Cardiovascular Disease and NASH. Liver Research, 1(2), 41–44. https://doi.org/10.17140/lroj-1-107

Issue

Vol. 1 No. 2 (2015): Volume 1 Issue 2 2015

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All content published in Liver Research (LROJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.